- Home
- INM vs CYBR Comparison
INM vs CYBR Comparison
Compare INM & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INM | CYBR |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 24.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | INM | CYBR |
|---|---|---|
| Price | $1.44 | $462.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 31 |
| Target Price | N/A | ★ $453.23 |
| AVG Volume (30 Days) | ★ 888.4K | 496.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,798,116.00 | ★ $1,302,851,000.00 |
| Revenue This Year | N/A | $36.30 |
| Revenue Next Year | N/A | $18.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.26 |
| 52 Week Low | $1.13 | $288.63 |
| 52 Week High | $8.27 | $526.19 |
Technical Indicators
Market Signals| Indicator | INM | CYBR |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 44.11 |
| Support Level | $1.28 | $455.76 |
| Resistance Level | $1.52 | $480.66 |
| Average True Range (ATR) | 0.11 | 9.54 |
| MACD | 0.03 | 1.60 |
| Stochastic Oscillator | 75.00 | 60.36 |
Price Performance
Historical ComparisonAbout INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.